granted patent: NOVEL HEV ANTIGENIC PEPTIDE AND METHODS

TitleNOVEL HEV ANTIGENIC PEPTIDE AND METHODS
Priority Date1999-09-30 CA19992283538
Inventors
Issue Date2001
Citation
WO Patent WO 0122916. World Intellectual Property Organization (WIPO), PatentScope, 2001 How to Cite?
AbstractA highly immunoreactive viral peptide, pE2, is disclosed which is derived form the carboxy-terminal end region of ORF2 region of the hepatitis E virus (HEV) genome. A unique feature of the novel pE2 peptide is that it possesses conformational antigenic determinants which are only exposed when monomers of the peptide associate with one another through non-covalent interactions to naturally form homodimers. The novel pE2 peptide is proven to be highly reactive with sera from patients having current or past infection with HEV which suggests that the homodimer may mimic certain structural features of the HEV capsid protein. Furthermore, the antigenic activity of the pE2 peptide is strictly conformational in nature and therefore, exhibits immunochemical reactivity only when the peptide exists in a dimeric form.; Consequently, the antigenic activity is lost upon dissociation of the dimers, but the activity is restored when the monomers reassociate to form dimers. Moreover, diagnostic methods useful in detecting and diagnosing HEV infection, and the use of a vaccine composition effective in preventing hepatitis E virus infection in which the novel pE2 peptide is utilized are also disclosed.
Persistent Identifierhttp://hdl.handle.net/10722/210541

 

DC FieldValueLanguage
dc.date.accessioned2015-06-17T07:04:16Z-
dc.date.available2015-06-17T07:04:16Z-
dc.date.issued2001-
dc.identifier.citationWO Patent WO 0122916. World Intellectual Property Organization (WIPO), PatentScope, 2001-
dc.identifier.urihttp://hdl.handle.net/10722/210541-
dc.description.abstractA highly immunoreactive viral peptide, pE2, is disclosed which is derived form the carboxy-terminal end region of ORF2 region of the hepatitis E virus (HEV) genome. A unique feature of the novel pE2 peptide is that it possesses conformational antigenic determinants which are only exposed when monomers of the peptide associate with one another through non-covalent interactions to naturally form homodimers. The novel pE2 peptide is proven to be highly reactive with sera from patients having current or past infection with HEV which suggests that the homodimer may mimic certain structural features of the HEV capsid protein. Furthermore, the antigenic activity of the pE2 peptide is strictly conformational in nature and therefore, exhibits immunochemical reactivity only when the peptide exists in a dimeric form.; Consequently, the antigenic activity is lost upon dissociation of the dimers, but the activity is restored when the monomers reassociate to form dimers. Moreover, diagnostic methods useful in detecting and diagnosing HEV infection, and the use of a vaccine composition effective in preventing hepatitis E virus infection in which the novel pE2 peptide is utilized are also disclosed.-
dc.relation.isreferencedby U S8524868 (B2) 2013-09-03-
dc.relation.isreferencedbyUS 2010143410 (A1) 2010-06-10 -
dc.relation.isreferencedby U S8715695 (B2) 2014-05-06-
dc.relation.isreferencedbyUS 2004052813 (A1) 2004-03-18 -
dc.relation.isreferencedby U S7615228 (B2) 2009-11-10-
dc.relation.isreferencedbyJP 2004525613 (A) 2004-08-26 -
dc.relation.isreferencedbyEP 2298793 (A2) 2011-03-23 -
dc.relation.isreferencedby E P2298793 (A3) 2011-06-29-
dc.relation.isreferencedbyUS 2010150962 (A1) 2010-06-17 -
dc.relation.isreferencedby J P5681337 (B2) 2015-03-04-
dc.relation.isreferencedbyEP 1331271 (A1) 2003-07-30 -
dc.relation.isreferencedby E P1331271 (A4) 2005-04-06 -
dc.relation.isreferencedby E P1331271 (B1) 2014-03-19-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License for public patent documents-
dc.titleNOVEL HEV ANTIGENIC PEPTIDE AND METHODS-
dc.typePatent-
dc.description.naturepublished_or_final_version-
dc.contributor.inventorIM, STANLEY-
dc.contributor.inventorNG, MUN HON-
dc.contributor.inventorZHANG, JI-ZHONG-
patents.identifier.applicationPC T/IB2000001393-
patents.description.assigneeUNIV HONG KONG [CN]; NG MUN HON [CN]; IM STANLEY [CN]; ZHANG JI ZHONG [CN] -
patents.description.countryWorld Intellectual Property Organization (WIPO) -
patents.date.publication2001-04-05-
patents.identifier.hkutechidMicro-1999-00251-9-
patents.date.application2000-09-28-
patents.date.priority1999-09-30 CA19992283538-
patents.description.ccwo-
patents.identifier.publicationWO 0122916-
patents.relation.family C N1195774 (C) 2005-04-06-
patents.relation.familyUS 7204989 (B1) 2007-04-17-
patents.relation.familyMX PA02003270 (A) 2003-08-20-
patents.relation.family J P4641695 (B2) 2011-03-02-
patents.relation.familyJP 2004500041 (A) 2004-01-08 -
patents.relation.familyHK 1051544 (A1) 2006-01-13-
patents.relation.familyEP 1461357 (A2) 2004-09-29 -
patents.relation.familyAU 7308200 (A) 2001-04-30-
patents.relation.familyBR 0014390 (A) 2003-09-30-
patents.relation.familyCA 2283538 (A1) 2001-03-30-
patents.relation.familyCN 1391579 (A) 2003-01-15 -
patents.description.kindA2-
patents.typePatent_granted-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats